MA54200A - Procédé industriel pour la préparation d'estétrol de pureté élevée - Google Patents

Procédé industriel pour la préparation d'estétrol de pureté élevée

Info

Publication number: MA54200A
Authority: MA; Morocco
Prior art keywords: estetrol; preparation; high purity; industrial process; industrial
Prior art date: 2019-09-03

Application number

MA054200A

Other languages

English (en)

Other versions

MA54200B1 (fr

Inventor

Ildikó Bacsa

Róbert Lovas

Sándor Mahó

Beatrix Mayer

Original Assignee

Richter Gedeon Nyrt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-09-03

Filing date

2020-09-02

Publication date

2022-04-27

2020-09-02 Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt

2022-04-27 Publication of MA54200A publication Critical patent/MA54200A/fr

2023-02-28 Publication of MA54200B1 publication Critical patent/MA54200B1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Gynecology & Obstetrics (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MA54200A 2019-09-03 2020-09-02 Procédé industriel pour la préparation d'estétrol de pureté élevée MA54200B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU1900315A HU231240B1 (hu)	2019-09-03	2019-09-03	Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
PCT/IB2020/058148 WO2021044302A1 (fr)	2019-09-03	2020-09-02	Procédé industriel pour la préparation d'estétrol de pureté élevée

Publications (2)

Publication Number	Publication Date
MA54200A true MA54200A (fr)	2022-04-27
MA54200B1 MA54200B1 (fr)	2023-02-28

Family

ID=89992977

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA54200A MA54200B1 (fr)	2019-09-03	2020-09-02	Procédé industriel pour la préparation d'estétrol de pureté élevée

Country Status (33)

Country	Link
US (1)	US11633406B2 (fr)
EP (1)	EP3877395B1 (fr)
JP (1)	JP7265087B2 (fr)
KR (1)	KR102871606B1 (fr)
CN (1)	CN114302889B (fr)
AU (1)	AU2020343497B2 (fr)
CA (1)	CA3147815C (fr)
CL (1)	CL2022000492A1 (fr)
CO (1)	CO2022003769A2 (fr)
CU (1)	CU24692B1 (fr)
DK (1)	DK3877395T3 (fr)
EC (1)	ECSP22022403A (fr)
ES (1)	ES2855923T3 (fr)
FI (1)	FI3877395T3 (fr)
GE (1)	GEP20247626B (fr)
HR (1)	HRP20230230T1 (fr)
HU (2)	HU231240B1 (fr)
IL (1)	IL290973B2 (fr)
JO (1)	JOP20220041A1 (fr)
LT (1)	LT3877395T (fr)
MA (1)	MA54200B1 (fr)
MD (1)	MD3877395T2 (fr)
MX (1)	MX2022002603A (fr)
MY (1)	MY206905A (fr)
NZ (1)	NZ786568A (fr)
PE (1)	PE20221418A1 (fr)
PH (1)	PH12022550388A1 (fr)
PL (1)	PL3877395T3 (fr)
PT (1)	PT3877395T (fr)
RS (1)	RS63966B1 (fr)
SI (1)	SI3877395T1 (fr)
WO (1)	WO2021044302A1 (fr)
ZA (1)	ZA202203557B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112022005359A2 (pt) *	2019-09-27	2022-07-19	Ind Chimica Srl	Processo de preparação de (15a,16a,17ss)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol(estetrol) e intermediários do referido processo
DE112021008305T5 (de) *	2021-10-01	2024-07-25	Industriale Chimica S.R.L.	VERFAHREN ZUR HERSTELLUNG VON (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) UND ESTETROL-MONOHYDRAT
HUP2500316A1 (en) *	2023-02-02	2025-11-28	Ind Chimica Srl	Process for preparing (15alpha,16alpha,17beta)-estra-1,3,5(10)-triene-3,15,16,17-tetrol (estetrol) monohydrate
CN117088928B (zh) *	2023-08-16	2025-09-09	湖北共同甾体药物研究院有限公司	用于制备高纯度雌四醇的工艺
CN119569803B (zh) *	2023-09-05	2025-09-16	秦皇岛紫竹药业有限公司	一种制备高纯度雌四醇的方法
HUP2400151A1 (hu)	2024-02-28	2025-09-28	Richter Gedeon Nyrt	Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE350041T1 (de)	2001-05-18	2007-01-15	Pantarhei Bioscience Bv	Pharmaceutishe zusammensetzung für die hormonersatztherapie
EP1260225A1 (fr)	2001-05-18	2002-11-27	Pantarhei Bioscience B.V.	Compositions pharmaceutiques pour le traitement hormonal substitutif
EP1390042B1 (fr)	2001-05-23	2007-11-28	Pantarhei Bioscience B.V.	Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale
WO2002094278A1 (fr)	2001-05-23	2002-11-28	Pantarhei Bioscience B.V.	Systeme d'administration de medicament a base d'oestrogenes tetrahydroxyles pour la contraception hormonale
ATE347365T1 (de)	2001-11-15	2006-12-15	Pantarhei Bioscience Bv	Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
DE60308679T2 (de)	2002-06-11	2007-08-16	Pantarhei Bioscience B.V.	Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung
EP1511498B1 (fr)	2002-06-11	2012-11-21	Pantarhei Bioscience B.V.	Methode de traitement de la peau humaine et composition pour le soin de la peau destinee a etre utilisee dans cette methode
EP1526856B1 (fr)	2002-07-12	2008-01-02	Pantarhei Bioscience B.V.	Composition pharmaceutique comprenant des derives d'estetrol utilises dans la therapie anticancereuse
US8987240B2 (en)	2002-10-23	2015-03-24	Pantarhei Bioscience B.V.	Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
AU2003279624A1 (en) *	2002-11-08	2004-06-07	Pantarhei Bioscience B.V.	Synthesis of estetrol via estrone derived steroids
WO2007081206A1 (fr)	2006-01-09	2007-07-19	Pantarhei Bioscience B.V.	Procédé de traitement d'un trouble vasculaire aigu
DE602008001783D1 (de)	2007-01-08	2010-08-26	Pantarhei Bioscience Bv	Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
EP2383279A1 (fr)	2011-07-19	2011-11-02	Pantarhei Bioscience B.V.	Procédé de préparation d'estetrol
ES2631359T3 (es)	2011-08-11	2017-08-30	Estetra S.P.R.L.	Uso del estetrol como anticonceptivo de emergencia
HRP20161282T1 (hr)	2011-10-07	2016-11-18	Estetra S.P.R.L.	Postupak za proizvodnju estetrola
EP2653163A1 (fr)	2012-04-19	2013-10-23	Université de Liège	Constituants estrogènes pour l'utilisation dans le traitement de troubles neurologiques
WO2013034780A2 (fr)	2012-12-20	2013-03-14	Crystal Pharma, S.A.U.	Procédé de préparation de l'estétrol et de composés analogues
US9988417B2 (en) *	2013-09-18	2018-06-05	Crystal Pharma, S.A.U.	Process for the preparation of estetrol
JP6447931B2 (ja)	2013-12-12	2019-01-09	ドネスタバイオサイエンスビー．ブイ．ＤｏｎｅｓｔａＢｉｏｓｃｉｅｎｃｅＢ．Ｖ．	エステトロール成分を含有する口腔内崩壊固体単位剤形
JP6813150B2 (ja)	2015-06-18	2021-01-13	エステトラソシエテプリーヴアレスポンサビリテリミテ	エステトロールを含有する口腔内崩壊錠
PL3310345T3 (pl)	2015-06-18	2021-10-18	Estetra Sprl	Ulegająca rozpadowi w jamie ustnej tabletka zawierająca estetrol
LT3701944T (lt)	2015-06-18	2022-04-11	Estetra Srl	Burnoje disperguojamas dozavimo vienetas, kurio sudėtyje yra estetrolio komponentas
KR102712911B1 (ko)	2016-08-05	2024-10-04	에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼	월경통 및 생리통의 관리방법
JP2018533542A (ja)	2016-10-28	2018-11-15	エステトラソシエテプリーヴアレスポンサビリテリミテ	月経困難症および月経痛の管理のための方法
ES2906380T3 (es)	2017-08-01	2022-04-18	Fund Sa	Terapia adyuvante para usar en el tratamiento del cáncer de próstata
CA3178181A1 (fr)	2018-02-07	2019-08-15	Estetra Srl	Composition contraceptive presentant des effets cardiovasculaires reduits
BR112022005359A2 (pt) *	2019-09-27	2022-07-19	Ind Chimica Srl	Processo de preparação de (15a,16a,17ss)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol(estetrol) e intermediários do referido processo

2019
- 2019-09-03 HU HU1900315A patent/HU231240B1/hu unknown
2020
- 2020-09-02 DK DK20768398.8T patent/DK3877395T3/da active
- 2020-09-02 CU CU2022000013A patent/CU24692B1/es unknown
- 2020-09-02 GE GEAP202015920A patent/GEP20247626B/en unknown
- 2020-09-02 CN CN202080061521.1A patent/CN114302889B/zh active Active
- 2020-09-02 JO JOP/2022/0041A patent/JOP20220041A1/ar unknown
- 2020-09-02 PL PL20768398.8T patent/PL3877395T3/pl unknown
- 2020-09-02 CA CA3147815A patent/CA3147815C/fr active Active
- 2020-09-02 MX MX2022002603A patent/MX2022002603A/es unknown
- 2020-09-02 JP JP2022511285A patent/JP7265087B2/ja active Active
- 2020-09-02 US US17/639,206 patent/US11633406B2/en active Active
- 2020-09-02 AU AU2020343497A patent/AU2020343497B2/en active Active
- 2020-09-02 PT PT207683988T patent/PT3877395T/pt unknown
- 2020-09-02 KR KR1020227010919A patent/KR102871606B1/ko active Active
- 2020-09-02 SI SI202030156T patent/SI3877395T1/sl unknown
- 2020-09-02 NZ NZ786568A patent/NZ786568A/en unknown
- 2020-09-02 HU HUE20768398A patent/HUE061427T2/hu unknown
- 2020-09-02 MY MYPI2022000866A patent/MY206905A/en unknown
- 2020-09-02 EP EP20768398.8A patent/EP3877395B1/fr active Active
- 2020-09-02 IL IL290973A patent/IL290973B2/en unknown
- 2020-09-02 HR HRP20230230TT patent/HRP20230230T1/hr unknown
- 2020-09-02 LT LTEPPCT/IB2020/058148T patent/LT3877395T/lt unknown
- 2020-09-02 FI FIEP20768398.8T patent/FI3877395T3/fi active
- 2020-09-02 PE PE2022000348A patent/PE20221418A1/es unknown
- 2020-09-02 RS RS20230112A patent/RS63966B1/sr unknown
- 2020-09-02 MA MA54200A patent/MA54200B1/fr unknown
- 2020-09-02 ES ES20768398T patent/ES2855923T3/es active Active
- 2020-09-02 MD MDE20210894T patent/MD3877395T2/ro unknown
- 2020-09-02 WO PCT/IB2020/058148 patent/WO2021044302A1/fr not_active Ceased
2022
- 2022-02-28 CL CL2022000492A patent/CL2022000492A1/es unknown
- 2022-03-24 EC ECSENADI202222403A patent/ECSP22022403A/es unknown
- 2022-03-28 ZA ZA2022/03557A patent/ZA202203557B/en unknown
- 2022-03-29 CO CONC2022/0003769A patent/CO2022003769A2/es unknown
- 2022-09-02 PH PH1/2022/550388A patent/PH12022550388A1/en unknown

Also Published As

Publication number	Publication date
NZ786568A (en)	2026-01-30
ES2855923T3 (es)	2023-04-28
ES2855923T1 (es)	2021-09-24
IL290973B2 (en)	2023-11-01
CU24692B1 (es)	2024-01-10
HUP1900315A1 (hu)	2021-03-29
LT3877395T (lt)	2023-02-27
WO2021044302A1 (fr)	2021-03-11
RS63966B1 (sr)	2023-03-31
PH12022550388A1 (en)	2024-01-29
MY206905A (en)	2025-01-15
KR102871606B1 (ko)	2025-10-16
CN114302889A (zh)	2022-04-08
IL290973B1 (en)	2023-07-01
KR20220071206A (ko)	2022-05-31
CO2022003769A2 (es)	2022-04-19
JP2022546016A (ja)	2022-11-02
CA3147815C (fr)	2023-03-28
DK3877395T3 (da)	2023-03-06
US11633406B2 (en)	2023-04-25
CU20220013A7 (es)	2022-10-11
US20220296609A1 (en)	2022-09-22
CA3147815A1 (fr)	2021-03-11
HU231240B1 (hu)	2022-04-28
JOP20220041A1 (ar)	2023-01-30
PE20221418A1 (es)	2022-09-20
PL3877395T3 (pl)	2023-05-08
JP7265087B2 (ja)	2023-04-25
PT3877395T (pt)	2023-02-02
CN114302889B (zh)	2023-08-29
EP3877395B1 (fr)	2022-12-07
HUE061427T2 (hu)	2023-07-28
MD3877395T2 (ro)	2023-05-31
ZA202203557B (en)	2022-11-30
BR112022003254A2 (pt)	2022-05-17
GEP20247626B (en)	2024-05-27
AU2020343497B2 (en)	2023-02-02
CL2022000492A1 (es)	2023-03-10
HRP20230230T1 (hr)	2023-04-14
MA54200B1 (fr)	2023-02-28
IL290973A (en)	2022-05-01
FI3877395T3 (fi)	2023-03-18
EP3877395A1 (fr)	2021-09-15
AU2020343497A1 (en)	2022-04-14
MX2022002603A (es)	2022-03-25
ECSP22022403A (es)	2022-04-29
SI3877395T1 (sl)	2023-03-31

Publication	Publication Date	Title
MA54200A (fr)	2022-04-27	Procédé industriel pour la préparation d'estétrol de pureté élevée
MA50859A (fr)	2020-09-09	Procédé pour la production d'une composition de lymphocytes t
EP3658552A4 (fr)	2021-06-23	Procédé amélioré pour la préparation de dérivés d'aminopyrimidine
EP4306505A4 (fr)	2025-01-15	Procédé de préparation de 1,1,2-trifluoroéthane
EP3683205A4 (fr)	2021-06-09	Procédé de préparation d'isocyanate aliphatique
EP4015519A4 (fr)	2023-07-12	Procédé de préparation d'asénapine
EP3288394A4 (fr)	2019-01-23	Procédé de préparation d'un produit alimentaire pour animaux de compagnie humide stérilisé
MA45768A (fr)	2019-06-05	Procédé pour la préparation de compositions d'immunoglobulines
EP3645529A4 (fr)	2021-03-10	Procédé pour la préparation de lifitegrast et d'intermédiaires de celui-ci
EP3613727A4 (fr)	2020-05-27	Procédé de préparation pour la coproduction de composés d'acrylamide et de formamide
EP3733648A4 (fr)	2021-07-07	Procédé de préparation d'acide 5r-benzyloxyaminopipéridin-2s-carboxylique ou d'un dérivé de celui-ci
EP3770280A4 (fr)	2021-01-27	Procédé pour la fabrication d'acier de haute pureté
EP3874056C0 (fr)	2023-06-14	Procédé enzymatique de préparation d'udp-glcnac
EP4021920A4 (fr)	2023-08-16	Procédé amélioré pour la préparation de chlorhydrate d'ételcalcétide
EP3768487A4 (fr)	2021-11-24	Procédé de micromoulages d'articles
EP3889572A4 (fr)	2021-11-24	Procédé de préparation d'échantillon
EP3927678A4 (fr)	2022-10-26	Procédé de séparation de produits d'oligomérisation oléfiniques (variants)
EP3663322A4 (fr)	2021-01-20	Procédé de préparation d'oligomère de butène
EP3974454A4 (fr)	2023-06-14	Procédé de préparation de sugammadex sodium de haute pureté
EP3788027A4 (fr)	2022-03-09	Procédé à recirculation pour la préparation d'éthylène glycol
EP3983373C0 (fr)	2023-08-23	Procédé en phase gazeuse pour la conversion de glycolaldéhyde à l'aide d'un agent d'amination
EP4201524A4 (fr)	2024-12-18	Procédé de production d'oléfines
MA51870A (fr)	2020-10-07	Procédé pour la préparation de composés coupleurs de médicaments
EP3841080A4 (fr)	2022-05-18	Procédé de production d'isobutylène de haute pureté
EP3722333A4 (fr)	2021-05-12	Procédé de préparation d'oligomère de polybutène